Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...
Amid ongoing speculation about how the biopharmaceutical sector will fare under Donald Trump's second presidency, the ...
Despite expanding and adding hundreds of new jobs in states like Ohio in the past year, biomanufacturing CDMO National ...
That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...
On an investment spree, Lilly will spend $3B to expand newly acquired injectables plant in Wisconsin
These days, with its revenue booming and a market cap swelling to twice the size of | Eli Lilly said it will spend $3 billion ...
LinkedIn likes have landed drugmakers in trouble once again. AstraZeneca—a repeat offender—and GSK were the subjects of the ...
Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...
Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
Robert F. Kennedy Jr.’s appointment last month to lead the U.S. Department of Health and Human Services (HHS) immediately ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback